Adjuvant Nivolumab Improves DFS in MIUC After Radical Surgery
CheckMate 274 investigators compared adjuvant nivolumab with placebo (PBO) in patients with MIUC who received cisplatin prior to radical surgery.
Genitourinary Cancers Symposium
No Association Between ADT and SARS-CoV-2 Infection in Prostate Cancer
The aim of this study was to determine whether androgen deprivation therapy (ADT) affords protection against SARS-CoV-2 infection in a population of patients with prostate cancer.
Survival Trends Analysis Shows Significant OS Gains for MIBC, But Not Urothelial Carcinoma
Investigators of this real-world analysis studied survival trends among patients with muscle-invasive bladder cancer (MIBC) and patients with metastatic urothelial carcinoma (UC).
Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
COVID-19 Adversely Affecting Patients With Genitourinary Cancers
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Adding a First-Generation Anti-Androgen to ADT for mCSPC Does Not Improve Outcomes
Real-world data show that a combination of a first-generation anti-androgen drug and androgen deprivation therapy is no better than ADT alone in improving outcomes among men with metastatic castration-sensitive prostate cancer.
High CTC Counts Predict Increased Progression, Mortality Risk in mHSPC
Investigators say they believe their study is the first to show a link between circulating tumor cell counts and progression-free and overall survival in men with metastatic hormone-sensitive prostate cancer.
Survival Benefit With First-Line Abiraterone for mCRPC Superior in Black Men
New real-world data suggest the presence of race-based differences in the therapeutic response to abiraterone.
PSA Screening Decline Implicated in Rise of Metastatic PCa at Diagnosis
States with larger declines in PSA screening experienced bigger increases in the incidence of metastatic prostate cancer at diagnosis, a recent study suggests.
Localized PCa Therapies Safely Delivered During COVID-19 Peak at NYC Center
A cancer center in New York City safely managed patients with localized prostate cancer during the height of the COVID-19 pandemic in 2020, providing insights for handling a second COVID-19 wave.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Genitourinary Cancers Symposium
